Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | GSK3A | P49840 | 3/20 | 0.47 |
| ▸ | FADS1 | O60427 | 2/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 8/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802064 | 0.89 | GSK3A (0.42) | GSK3BGSK3AFADS1TRPA1CYP1A2 | |
| SCHEMBL12619897 | 0.87 | GSK3A (0.42) | GSK3BGSK3AFADS1MAP2K4TRPA1 | |
| SCHEMBL802321 | 0.81 | GSK3A (0.56) | GSK3BGSK3AFADS1ABL1EGFR | |
| SCHEMBL802068 | 0.81 | FADS1 (0.41) | FADS1TRPA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL802710 | 0.78 | GSK3A (0.42) | GSK3BGSK3AFADS1TRPA1EGFR | |
| SCHEMBL12619882 | 0.77 | USP1 (0.43) | GSK3BGSK3AFADS1TRPA1CYP1A2 | |
| SCHEMBL801635 | 0.77 | FADS1 (0.49) | GSK3BGSK3AFADS1MAP2K4CYP1A2 | |
| SCHEMBL802067 | 0.76 | AURKA (0.38) | GSK3BGSK3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL801665 | 0.76 | FADS1 (0.51) | GSK3BGSK3AFADS1CYP1A2CYP3A4 | |
| SCHEMBL802027 | 0.73 | FADS1 (0.46) | GSK3BGSK3AFADS1TRPA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3B 1/4885GSK3A 2/4885FADS1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.